Fcγ receptor IIA H/R131 polymorphism in patients with antiphospholipid antibodies

Thrombosis and Haemostasis

Volumn 79, Issue 5, 1998, Pages 924-927

  Atsumi, Tatsuya ^a   Caliz, Rafael ^a   Amengual, Olga ^a   Khamashta, Munther A ^a   Hughes, Graham R V ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FC RECEPTOR; IMMUNOGLOBULIN G2; PHOSPHOLIPID ANTIBODY; FC GAMMA RECEPTOR IIA; LEUKOCYTE ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BINDING AFFINITY; CAUCASIAN; CLINICAL FEATURE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SPONTANEOUS ABORTION; THROMBOCYTOPENIA; VEIN THROMBOSIS; BLOOD; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; MIDDLE AGED; PREGNANCY;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIGENS, CD; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PREGNANCY; RECEPTORS, IGG;

EID: 0031596890     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615095     Document Type: Article

References (36)

1. Hughes GRV. The antiphospholipid syndrome: ten years on. Lancet 1993; 342: 341-4.
2. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJC, Barbui T, Zwaal RFAZ, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 952-3.
3. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177-8.
4. 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4.
5. 2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J Immunol 1994; 152: 653-9.
6. 2-glycoprotein I as an anticardiolipin cofactor determined using deleted mutants expressed by a Baculovirus system. Blood 1996; 87: 3262-70.
7. 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457-62.
8. 2-glycoprotein I in the absence of phospholipid. J Immunol 1995; 154: 954-60.
9. Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" antibodies. Blood 1994; 84: 2854-67.
10. Roubey RAS. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 1996; 39: 1444-54.
11. Arnout J. The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin-induced thrombocytopenia. Thromb Haemost 1996; 75: 536-41.
12. Chong BH, Pitney WR, Castaldi PA. Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis and platelet aggregation. Lancet 1982; 2: 1246-9.
13. Chong BH, Pilgrim RL, Cooley MA, Chesterman CN. Increased expression of platelet IgG Fc receptors in immune heparin-induced thrombocytopenia. Blood 1993; 81: 988-93.
14. Anderson GP. Insights into heparin-induced thrombocytopenia. Br J Haematol 1992; 80: 504-8.
15. Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, Silverstein RL. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96: 2211-9.
16. Del PaPa N, Guidali L, Sala A, Buccellati C, Khamashta MA, Ichikawa K, Koike T, Balestrieri G, Tincani A, Hughes GRV, Meroni PL. Endothelial cells as target for antiphospholipid antibodies. Arthritis Rheum 1997; 40: 551-61.
17. Brooks DG, Qui WQ, Luster AD, Ravetch JV. Structure and expression of human IgG FcRII(CD32). J Exp Med 1989; 170: 1369-85.
18. van de Winkel JGJ, Capel PJA. Human IgG Fc receptor heterogeneity. Immunol Today 1993; 14: 215-21.
19. 2 binding. J Immunol 1991; 147: 1338-43.
20. Clark MR, Stuart SG, Kimberly RP, Ory PA, Goldstein IM. A single amino acid distinguishes the high-responder from the low-responder form of Fc receptor II on human monocytes. Eur J Immunol 1991; 21: 1911-6.
21. Kimberly RP, Salmon JE, Edberg JC. Receptors for immunoglobulin G: molecular diversity and implications for disease. Arthritis Rheum 1995; 38: 306-14.
22. Yee AMF, Ng SC, Sobel RE, Salmon JE. Fcγ RIIA polymorphism as a risk factor for invasive pneumococcal infection in systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1180-2.
23. Salmon JE, Millard S, Schachter LA, Arnett FC, Ginzler EM, Gourley MF, Ramsey-Goldman R, E. Peterson MG, Kimberly RP. FcγRIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1996; 97: 1348-54.
24. 2 glycoprotein I antibodies in autoimmune patients. Clin Exp Immunol 1994; 95: 310-5.
25. Harris EN. Antiphospholipid antibodies. Br J Haematol 1990; 74: 1-9.
26. Jiang XM, Arepally G, Poncz M, McKenzie SE. Rapid detection of the FcγRIIA-H/R131 ligand-binding polymorphism using an allele-specific restriction enzyme digestion (ASRED). J Immunol Methods 1996; 199: 55-9.
27. 2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol 1996; 35: 1239-43.
28. Harris EN, Gharavi AE, Patel BM, Hughes GRV. Evaluation of the anticardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987; 68: 215-22.
29. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Suzuki T, Yoshida S, Koike T. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol 1992; 148: 3885-91.
30. Tannenbaum SH, Finko R, Cines DB. Antibody and immune complexes induce tissue factor production by human endothelial cells. J Immunol 1986; 137: 1532-7.
31. Atsumi T, Khamashta MA, Amengual O, Hughes GRV. Up-regulated tissue factor expression in antiphospholipid syndrome. Thromb Haemost 1997; 77: 222-3.
32. Jurado M, Paramo JA, Gutierrez-Pimentel M, Rocha E. Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders. Thromb Haemost 1992; 68: 516-20.
33. Kelton JG, Sheridan D, Santos A, Smith J, Steeves K, Smith C, Brown C, Murphy WG. Heparin-induced thrombocytopenia: Laboratory studies. Blood 1988; 72: 925-30.
34. Brandt JT, Isenhart, CE, Osborne JM, Ahmed A, Anderson CL. On the role of Fcγ-RIIa phenotype in heparin-induced thrombocytopenia. Thromb Haemost 1995; 74: 1564-72.
35. Burgess JK, Lindeman R, Chesterman CN, Chong BH. Single amino acid mutation of Fcγ receptor is associated with the development of heparin-induced thrombocytopenia. Br J Haematol 1995; 91: 761-6.
36. Arepally G, McKenzie SE, Jiang XM, Poncz M, Cines DB. FcγRIIA H/R131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis. Blood 1997; 89: 370-5.